MARKET

NVTA

NVTA

Invitae
NYSE

Real-time Quotes | Nasdaq Last Sale

39.04
-2.97
-7.07%
After Hours: 38.50 -0.54 -1.38% 16:19 03/03 EST
OPEN
41.41
PREV CLOSE
42.01
HIGH
41.85
LOW
37.71
VOLUME
5.30M
TURNOVER
--
52 WEEK HIGH
61.59
52 WEEK LOW
7.42
MARKET CAP
7.68B
P/E (TTM)
-8.8818
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Pharming Group And Invitae Launch NavigateAPDS Genetic Testing Program
reuters.com · 1d ago
Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases ...
PR Newswire · 1d ago
Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research
The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis by Emergen Research. Due to the increasing prevalence of cancer, the market for global Hematologic Malignancies Testing i...
GlobeNewswire · 2d ago
Invitae Files Automatic Registration Statement On Behalf Of Certain Stockholders
MT Newswires · 2d ago
Global Rare Disease Genetic Testing Market 2020 Growth, Industry Trend, Sales Revenue, Size by Regional Forecast to 2025
Feb 28, 2021 (CDN Newswire via Comtex) -- Global Rare Disease Genetic Testing Market 2020 by Company, Type and Application, Forecast to 2025 is a resource,...
CDN Newswire · 3d ago
10-K: INVITAE CORP
(EDGAR Online via COMTEX) -- ITEM 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
How Cathie Wood plans to navigate choppy market waters now that she manages $54 billion
Ark Invest's assets under management have ballooned to nearly $54 billion from about $3.9 billion this time last year.
CNBC.com · 5d ago
United States Non-Invasive Prenatal Testing Market Size to Witness Huge Growth by 2026
Feb 26, 2021 (Market Insight Reports) -- Selbyville, Delaware The research report titled 'United States Non-Invasive Prenatal Testing Market 2019 - 2026',...
Market Insight Reports · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVTA. Analyze the recent business situations of Invitae through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVTA stock price target is 54.60 with a high estimate of 65.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 459
Institutional Holdings: 182.57M
% Owned: 92.84%
Shares Outstanding: 196.65M
TypeInstitutionsShares
Increased
137
29.39M
New
129
7.69M
Decreased
71
4.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.15%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Sean George
Chief Financial Officer
Shelly Guyer
Chief Operating Officer
Kenneth Knight
Chief Accounting Officer
Robert Werner
General Counsel/Secretary
Thomas Brida
Other
Robert Nussbaum
Other
Katherine Stueland
Other
Karthik Suri
Lead Director/Independent Director
Christine Gorjanc
Director
Kimber Lockhart
Director
Jason Myers
Independent Director
Eric Aguiar
Independent Director
Geoffrey Crouse
Independent Director
Chitra Nayak
  • Dividends
  • Splits
  • Insider Activity
No Data
About NVTA
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Webull offers kinds of Invitae Corp stock information, including NYSE:NVTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVTA stock methods without spending real money on the virtual paper trading platform.